In November the Food and Drug Administration (FDA) issued letters to various companies selling products contained cannabidiol (CBD), citing concerns that certain products may appeal to.
The Food and Drug Administration (FDA) issued warning letters to five companies late last month on Monday, November 21, 2022, claiming that they are illegally selling products containing cannabidiol (CBD).
These letters continue to stress the need for Congress to enact legislation that will force the FDA to finally establish a regulatory pathway to govern CBD products intended for human and animal consumption.
On November 16, 2022, the Food and Drug Administration (FDA) issued five new warning letters to various companies making edible products containing cannabidiol (CBD) and/or.
The U.S. Food and Drug Administration (FDA) has posted warning letters to five companies that is believes are in violation of illegally selling products containing cannabidiol (CBD).